While an acquired loss of activity in CYP2C19 has been described in the literature in cancer patients39, the real impact of this discrepancy between CYP2C19 pheno- and genotype in breast cancer patients receiving adjuvant tamoxifen is unclear. The gene discussed is CYP2C19; the disease is breast cancer.